All Articles

When it comes to justifying the need for navigation resources, building a business case is a nonnegotiable, according to Lindsey Reed, MBA, BSN, RN, OCN, ONN-CG, director of navigation for Sarah Cannon in the HCA Midwest Division, and Nicole Centers, MBA, BSN, RN, OCN, CBCN, CN-BN, executive director of Oncology Service Line at Wellstar Healthcare System in Marietta, GA.

Whether we are displaying it or experiencing it, implicit bias is an unavoidable part of life, according to Stephanie L. Graff, MD, FACP, director of breast oncology at the Lifespan Cancer Institute.

Renal-cell carcinoma (RCC) is among the 10 most common cancers for men and women in the United States and has been shown to cause considerable burden in both patients and their caregivers.

As part of Stony Brook University, a flagship university of the State University of New York system, the Stony Brook Cancer Center provides a full spectrum of services from primary to tertiary care across both inpatient and outpatient sites.

Please join us live or virtually this May 17-21 in Orlando, FL, for the AONN+ Midyear Conference—the only conference dedicated to oncology nurse and patient navigators!

This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.

The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.

Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM.